HUDDINGE, Sweden, Jan. 31, 2003 (PRIMEZONE) -- The Board of Medivir (Stockholm:MVIRb) has appointed Lars Adlersson to the position as CEO and President beginning March 1, 2003.
Lars Adlersson is 38 years old and has a B.Sc. (Econ and BA) from Uppsala University. He has also studied Management and Marketing at the Institute of Management in Sigtuna (SE) and Brussels, London Business School and Duke University in USA.
Lars Adlersson has held several positions in Janssen Pharma and the Glaxo Group. During his time in Glaxo he has been Vice President and General Manager in Sweden and Austria and before then, Marketing Director in several therapeutic areas. Most recently, Lars has been at Handelsbanken Securities, where, since 2002, he has been working as a Senior Analyst within the Healthcare Team.
"The combination of international work, experience from the Healthcare industry and the big pharma companies, especially the demands from a marketing viewpoint on the results of the research, and his economical education will be of use and be important to Medivir," commented Anders Vedin, Chairman of the Board in Medivir.
For further information, please contact:
Bo Oberg, CEO phone +46 8 5468 3100 Anders Vedin, Chairman of the Board phone +46 8 5468 3100 Rein Piir, CFO and IR phone +46 8 5468 3123 or +46 708 53 72 92
The Medivir Group
Medivir is an innovative and specialized research company active in the pharmaceuticals sphere, located in Cambridge, U.K., and Huddinge, Sweden. Medivir's research focuses on the development of new pharmaceutical compounds as inhibitors of target enzymes with protease or polymerase activity.
The group comprises Medivir AB, the subsidiaries Medivir U.K. Ltd. and CCS AB, plus second-tier subsidiaries CCS (U.K.) Ltd. and Nordic Care Sweden AB. Medivir has been listed on the Stockholm Stock Exchange since 1996.
The research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, rheumatoid arthritis, asthma, multiple sclerosis and organ/graft rejection. Medivir has four projects in clinical development. Of these, two are moving towards Phase III trials after having completed Phase II trials. One is in Phase I and one is in Phase II. Medivir's pre-clinical research encompasses a number of projects, of which one is on its way towards and two are in the lead optimization phase and one is in the late pre-clinical development stage. A further ten activities are in the explorative stage.
For more information about Medivir, visit the company's Website at www.medivir.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2003/01/31/20030131BIT00200/wkr0001.doc www.waymaker.net/bitonline/2003/01/31/20030131BIT00200/wkr0002.pdf